Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06984484Not ApplicableRecruiting

Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease

Role: lead

NCT06681012Not ApplicableRecruiting

Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome

Role: lead

NCT05959824Not ApplicableUnknown

Devintec OR-AT0222 Oral Gel for the Treatment of Canker Sores: A Double Blind, Randomized, Placebo Controlled Clinical Investigation

Role: lead

NCT05240521Not ApplicableUnknown

Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C

Role: lead

All 4 trials loaded